@article{76acec4f654f42b3b63267e0701dfb88,
title = "Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease",
abstract = "Matrix Gla protein (MGP) is a potent inhibitor of vascular calcification (VC) and requires carboxylation by vitamin K to exert calcification inhibition. Chronic kidney disease (CKD) patients undergo early vascular aging often involving extensive VC. The present cross-sectional study investigated the association between circulating dp-ucMGP levels, MGP expression in vascular tissue and MGP polymorphisms. In 141 CKD stage 5 patients, CAC score was significantly increased in the highest tertile of dp-ucMGP (p=0.002), and a high medial VC score was associated with elevated dp-ucMGP levels. MGP vascular expression was associated with increased circulating dp-ucMGP and CAC scores. MGP SNP analysis revealed that patients homozygous for the C allele of the rs1800801 variant had a higher CAC score (median 15 [range 0-1312]) compared to patients carrying a T allele (median 0 [range 0-966] AU). These results indicate that plasma levels of dp-ucMGP are an independent predictor of increased VC in CKD5 patients and correlate with both higher CAC scores and degree of medial calcification. Additionally, high vascular expression of MGP was associated with higher CAC scores and plasma dp-ucMGP levels. Taken together, our results support that MGP is involved in the pathogenesis of VC.",
keywords = "STAGE RENAL-DISEASE, CORONARY-ARTERY CALCIFICATION, CARDIOVASCULAR EVENTS, RISK, SUPPLEMENTATION, OSTEOCALCIN, EXPRESSION, MARKER",
author = "Jaminon, {Armand M. G.} and Lu Dai and Qureshi, {Abdul Rashid} and Pieter Evenepoel and Jonaz Ripsweden and Magnus Soderberg and Anna Witasp and Hannes Olauson and Schurgers, {Leon J.} and Peter Stenvinkel",
note = "Funding Information: This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie grant agreement No 722609 (INTRICARE). Peter Stenvinkels research was supported by grants provided by the Stockholm County Council,”Strategic Research Programme in Diabetes at Karolinska Institutet (Swedish Research Council grant No 2009-1068)”. Open access funding provided by Karolinska Institute. Funding Information: Dr. Schurgers reports consultancy fee from Immunodiagnostic systems (IDS), outside the submitted work and grants from NattoPharma outside the submitted work; Dr. Evenepoel reports personal fees from Vifor FMC, personal fees from Amgen, personal fees from Medice, grants from Sanofi outside the submitted work. Dr. Stenvinkel reports personal fees from Astellas, grants and personal fees from Astra Zeneca, personal fees from Reata, personal fees from Corvidia, personal fees from Baxter, personal fees from Pfizer, outside the submitted work. All other authors don{\textquoteright}t have competing interests. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = apr,
day = "20",
doi = "10.1038/s41598-020-63013-8",
language = "English",
volume = "10",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",
}